Tolaney SM - Search Results

1

Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.

Tolba MF, Elghazaly H, Bousoik E, Elmazar MMA, Tolaney SM. Tolba MF, et al. Among authors: tolaney sm. Clin Transl Oncol. 2021 Oct;23(10):1979-1994. doi: 10.1007/s12094-021-02613-w. Epub 2021 Apr 19. Clin Transl Oncol. 2021. PMID: 33871826 Review.

2

Mechanisms of trastuzumab resistance in breast cancer.

Tolaney SM, Krop IE. Tolaney SM, et al. Anticancer Agents Med Chem. 2009 Mar;9(3):348-55. doi: 10.2174/1871520610909030348. Anticancer Agents Med Chem. 2009. PMID: 19275526 Review.

3

The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.

Waks AG, Tolaney SM. Waks AG, et al. Among authors: tolaney sm. Future Oncol. 2015;11(24):3261-71. doi: 10.2217/fon.15.240. Epub 2015 Nov 13. Future Oncol. 2015. PMID: 26634944 Review.

4

Optimal Management of Early and Advanced HER2 Breast Cancer.

Hurvitz SA, Gelmon KA, Tolaney SM. Hurvitz SA, et al. Among authors: tolaney sm. Am Soc Clin Oncol Educ Book. 2017;37:76-92. doi: 10.1200/EDBK_175630. Am Soc Clin Oncol Educ Book. 2017. PMID: 28561711 Free article. Review.

5

Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.

Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L. Barroso-Sousa R, et al. Among authors: tolaney sm. Cancer. 2018 Mar 15;124(6):1111-1121. doi: 10.1002/cncr.31200. Epub 2018 Jan 3. Cancer. 2018. PMID: 29313945 Free article. Review.

6

Optimal treatment of early stage HER2-positive breast cancer.

Pernas S, Barroso-Sousa R, Tolaney SM. Pernas S, et al. Among authors: tolaney sm. Cancer. 2018 Dec 1;124(23):4455-4466. doi: 10.1002/cncr.31657. Epub 2018 Oct 6. Cancer. 2018. PMID: 30291791 Free article. Review.

7

How we treat locally advanced HER2-positive breast cancer.

Exman P, Pernas S, Tolaney SM. Exman P, et al. Among authors: tolaney sm. Clin Adv Hematol Oncol. 2019 May;17(5):271-280. Clin Adv Hematol Oncol. 2019. PMID: 31188804 No abstract available.

8

Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.

Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Goel S, et al. Among authors: tolaney sm. Clin Breast Cancer. 2019 Dec;19(6):399-404. doi: 10.1016/j.clbc.2019.05.010. Epub 2019 May 30. Clin Breast Cancer. 2019. PMID: 31235441 Clinical Trial.

9

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.

Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes M, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop IE, Dillon D, Winer EP, Wagle N, Lin NU, Mittendorf EA, Van Allen EM, Tolaney SM. Barroso-Sousa R, et al. Among authors: tolaney sm. Clin Cancer Res. 2020 Jun 1;26(11):2565-2572. doi: 10.1158/1078-0432.CCR-19-3507. Epub 2020 Feb 4. Clin Cancer Res. 2020. PMID: 32019858 Free PMC article.

10

Role of Immunotherapy in Triple-Negative Breast Cancer.

Keenan TE, Tolaney SM. Keenan TE, et al. Among authors: tolaney sm. J Natl Compr Canc Netw. 2020 Apr;18(4):479-489. doi: 10.6004/jnccn.2020.7554. J Natl Compr Canc Netw. 2020. PMID: 32259782 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

311 results

Search Page